Overall, 5–10% of breast cancers are attributed to the inheritance of a mutation in the tumor suppressor BRCA1 gene (BRCA1m).5 Yet, up to 70–90% of BRCA1m carriers develop TNBC.6 There are variable forms of BRCA1m, which increases the difficulty of potentially targeting those specific mutations for TNBC therapy. This evidence concerns the gene BRCA1 and breast cancer.